NextCell Pharma AB

NextCell Pharma operates in medical technology. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.

Quotes for NextCell Pharma AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Mathias Svahn

Chairperson of the Board

  • Anders Essen-Möller

Board

  • Camilla Myhre Sandberg
  • Edvard Smith
  • Hans-Peter Ekre
  • Niclas Löwgren
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    NextCell Pharma Sedermeradagen Stockholm 2017

    VD Mathias Svahn - HemmaHos NextCell

    VD Mathias Svahn presenterar bolaget.

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 14,88 14,88 2025-03-27
    Diamyd Medical AB 6,88 6,88 2025-03-27
    Mabtech Group AB 2,43 2,43 2025-03-27
    Nordnet Pensionsförsäkring 2,42 2,42 2025-03-27
    Nordea Liv & Pension 1,65 1,65 2025-03-27
    Filip Wirefors 1,50 1,50 2025-03-27
    Bioall AB 1,12 1,12 2025-03-27
    Christer Jansson 1,04 1,04 2025-03-27
    Robin Bertilsson 0,99 0,99 2025-03-27
    Konstruktions o Försäljnings AB KFAB 0,89 0,89 2025-03-27

    Annual reports, prospectus etc.